About Gedea Biotech
Gedea Biotech is a company based in Lund (Sweden) founded in 2015 by Sophie Manner and Helena Strevens. Gedea Biotech has raised $1.63 million across 7 funding rounds from investors including European Commission, EIT Health and European Union. Gedea Biotech offers products and services including pHyph. Gedea Biotech operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
- Headquarter Lund, Sweden
- Founders Sophie Manner, Helena Strevens
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gedea Biotech Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.63 M (USD)
in 7 rounds
-
Latest Funding Round
$2.71 M (USD), Grant
Feb 29, 2024
-
Investors
European Commission
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gedea Biotech
Gedea Biotech offers a comprehensive portfolio of products and services, including pHyph.
Antibiotic-free treatment for bacterial vaginosis with rapid symptom relief.
People of Gedea Biotech
Unlock access to complete
Unlock access to complete
Funding Insights of Gedea Biotech
Gedea Biotech has successfully raised a total of $1.63M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $2.71 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gedea Biotech
Gedea Biotech has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include European Commission, EIT Health and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Healthcare startups are accelerated and incubated through specialized programs.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by corporate-backed Almi Invest.
|
Locked | Locked | Locked |
Investor details for Gedea Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gedea Biotech
Investment portfolio details for Gedea Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gedea Biotech
Detailed financials for Gedea Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gedea Biotech Comparisons
Peer comparison for Gedea Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gedea Biotech
Gedea Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
|
| Locked | Locked | Locked |
Late-stage biopharma antibiotics for gynecological infections are developed.
|
|
| Locked | Locked | Locked |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
Detailed competitors of Gedea Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gedea Biotech
Complete news archive for Gedea Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gedea Biotech
Gedea Biotech was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Gedea Biotech is headquartered in Lund, Sweden.
Annette Safholm is the current CEO of Gedea Biotech.
Gedea Biotech is a funded company, having raised a total of $1.63M across 7 funding rounds to date.
Provider of therapeutics for treating vaginal microbial infections. It offers non-antibiotic based small molecule drug pHyph which is under clinical study 2, it has the ability to lower the pH and is effective against both bacterial and fungal infection.
Gedea Biotech's top competitors include Insmed, MaaT Pharma and Basilea.
Gedea Biotech offers pHyph.
Gedea Biotech has 5 investors. Key investors include European Commission, EIT Health, European Union, EIC Fund, and Almi Invest.